Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus

What Was Tested

This randomized controlled trial paper looks at Exenatide.

Who Took Part

The abstract describes 82 patients taking part.

By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.

In this interim 82-week analysis, 150 (total cohort) of an eligible population of 183 patients opted to continue exenatide treatment in an uncontrolled open-label extension of a 30-week double-blind, placebo-controlled trial.

Of these, 92 patients (completer cohort) achieved 82 weeks of exenatide therapy.

How the Study Was Run

In design terms this was a randomized, double-blind, open-label and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got Exenatide and who got the comparison, which limits bias.

As a double-blind Exenatide study, the assignments were hidden from both participants and investigators until the end.

Everyone knew when Exenatide was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

The comparison arm used a placebo, so changes seen with Exenatide could be set against what happens without it.

Patients continued metformin throughout the study.

What Was Measured

Topics PubMed links to this paper include Cardiovascular Diseases, Diabetes Mellitus, Type 2, Exenatide, Glycated Hemoglobin, Hypoglycemic Agents, Lipids and Metformin.

What This Means in Plain Language

The paper is a randomized, double-blind and open-label study of Exenatide in 82 patients.

The abstract goes on to report its results in about 8 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2006 (Diabetes, obesity & metabolism), a journal based in England.

More context: the Exenatide compound page.